At the dawn of biosimilar insulins
The European Medicines Agency introduced the term 'biosimilars' into their legislation in 2004 to allow for marketing authorisation of biological therapeutics and in 2014 Abasria® was approved for the treatment of type 1 and type 2 diabetes
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: ebercott Tags: Diabetes Featured Articles Source Type: news
More News: Diabetes | Diabetes Type 1 | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | European Medicines Agency (EMA) | Marketing